Dima, D., Vazquez-Martinez, M. A., Davis, J. A., Goel, U., Afrough, A., Sannareddy, A., … Shune, L. O. (2024). Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium. In Blood (Vol. 144, pp. 897–897). American Society of Hematology. https://doi.org/10.1182/blood-2024-203409

Dima, Danai, Mariola A. Vazquez-Martinez, James A. Davis, Utkarsh Goel, Aimaz Afrough, Aishwarya Sannareddy, Oren Pasvolsky, et al. “Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium.” In Blood, 144:897–897. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-203409.

Dima D, Vazquez-Martinez MA, Davis JA, Goel U, Afrough A, Sannareddy A, et al. Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium. In: Blood. American Society of Hematology; 2024. p. 897–897.

Dima, Danai, et al. “Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 897–897. Crossref, doi:10.1182/blood-2024-203409.

Dima D, Vazquez-Martinez MA, Davis JA, Goel U, Afrough A, Sannareddy A, Pasvolsky O, Razzo B, Banerjee R, Khouri J, Grajales-Cruz A, Lieberman-Cribbin A, Rana MS, Julian K, DeJarnette S, Portuguese AJ, Gaballa MR, De Avila G, Susanibar-Adaniya S, Raza S, Herr MM, Ouchveridze E, Richards T, Hosoya H, Mikkilineni L, Kaur G, Schrum D, Castaneda O, Rossi A, Lin C, Forsberg PA, Lin Y, Atrash S, Sborov DW, Shain KH, Voorhees PM, Richard S, Garfall AL, Hansen DK, Sidana S, Patel KK, Cowan AJ, Anderson LD, Lee HC, Anwer F, Ferreri C, Shune LO. Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood. American Society of Hematology; 2024. p. 897–897.